Lakefront Biotherapeutics NV annual r&d spending
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Lakefront Biotherapeutics NV R&D Spending Growth & History (LKFT)
Lakefront Biotherapeutics NV's r&d spending was €459.4M for fiscal 2025.
View full Lakefront Biotherapeutics NV company overviewLakefront Biotherapeutics NV annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €459.4M | €124.0M | +36.95% |
| 2024 | 2024-12-31 | €335.5M | €94.2M | +39.03% |
| 2023 | 2023-12-31 | €241.3M | −€28.5M | −10.56% |
| 2022 | 2022-12-31 | €269.8M | −€50.7M | −15.82% |
| 2021 | 2021-12-31 | €320.5M | −€203.2M | −38.80% |
| 2020 | 2020-12-31 | €523.7M | €103.6M | +24.66% |
| 2019 | 2019-12-31 | €420.1M | €103.9M | +32.85% |
| 2018 | 2018-12-31 | €316.2M | €97.7M | +44.72% |
| 2017 | 2017-12-31 | €218.5M | €78.9M | +56.55% |
| 2016 | 2016-12-31 | €139.6M | €9.9M | +7.60% |
| 2015 | 2015-12-31 | €129.7M | — | — |
Lakefront Biotherapeutics NV quarterly r&d spending
Q2.17
Q2.18
Q2.19
Q2.20
Q2.21
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €25.5M | −€69.8M | −73.21% |
| Q1 2026 | 2026-03-31 | €31.0M | −€151.8M | −83.06% |
| Q4 2025 | 2025-12-31 | €107.5M | — | — |
| Q3 2025 | 2025-09-30 | €73.9M | — | — |
| Q2 2025 | 2025-06-30 | €95.3M | — | — |
| Q1 2025 | 2025-03-31 | €182.8M | — | — |
| Q2 2021 | 2021-06-30 | €138.9M | −€8.6M | −5.82% |
| Q2 2020 | 2020-06-30 | €147.4M | €53.1M | +56.24% |
| Q2 2019 | 2019-06-30 | €94.4M | €12.7M | +15.54% |
| Q2 2018 | 2018-06-30 | €81.7M | €33.7M | +70.23% |
| Q2 2017 | 2017-06-30 | €48.0M | — | — |
Lakefront Biotherapeutics NV r&d spending trends
Over the last five fiscal years, Lakefront Biotherapeutics NV's r&d spending decreased from €523.7M to €459.4M, a change of −€64.2M. The latest reported quarter, Q2 2026, shows €25.5M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lakefront Biotherapeutics NV source filings ↗